Anxiety disorders/symptoms: One study found that nabilone (a synthetic analog of THC) improved anxiety symptoms. Two RCTs found that CBD acutely reduced anxiety.
Posttraumatic stress disorder: One study found that nabilone reduced PTSD-related nightmares.
Schizophrenia: Three studies assessed oral CBD, two of which reported improvements in symptoms. Two studies assessed rimonabant (a drug that suppresses CB1 signaling), with no significant effects observed. One study assessed intravenous delta-9-THC and reported a worsening of symptoms.
Anorexia nervosa: One study found that dronabinol (another synthetic THC analog) increased average body weight.
Cannabis use disorder: Four studies found benefits of dronabinol on withdrawal symptoms, three of which reported a reduction in cannabis use. One found no effects of nabilone on cannabis use. Three studies found that nabiximols (a THC/CBD extract) reduced withdrawal symptoms, and one study found that nabiximols reduced cannabis consumption.
Opioid use disorder: Two studies found that dronabinol helped to reduce withdrawal symptoms. However, one of these studies reported sedation and tachycardia at high doses. One study also found that CBD reduced anxiety and craving responses following heroin abstinence.
Tobacco use disorder: CBD and rimonabant reduced cigarette smoking in one study each.
Attention deficit hyperactivity disorder: One study found that nabiximols did not affect symptoms.
Tourette's disorder: Two studies found benefits of dronabinol on tics and OCD in Tourette's disorder
Obsessive-compulsive disorder: One study assessing smoked cannabis found no effects of high THC or high CBD cannabis.

Quantitative analyses found that dronabinol, but not nabiximols, improved scores on the withdrawal discomfort scale among participants with cannabis use disorder, whereas dronabinol did not affect opioid use disorder.

Cannabinoids and cannabinoid-based products for psychiatric disorders Original paper